Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma
The Brightline-4 study is a Phase III clinical trial testing a new experimental drug named BI 907828 for people with advanced dedifferentiated liposarcoma. This type of cancer affects soft tissues in the body. Researchers want to understand how safe this new drug is and how well it works in patients, regardless of whether they have had prior treatment or not. The study involves giving a specific dose of BI 907828 and carefully monitoring patients for any side effects or changes in their cancer. It's a key stage in research to see if this treatment could become a new option for patients. All types of people, male and female, aged 18 and older, are being considered for this study.
At a glance
What is this study about?
This clinical trial, known as Brightline-4, is a significant study exploring a new medication called BI 907828 for a specific type of cancer called dedifferentiated liposarcoma. This is a type of cancer that can develop in the soft tissues of the body. The goal of this study is to find out if this new drug is safe to use and if it can help treat this cancer effectively. It's a 'Phase III' study, which means it's one of the final steps before a new drug might be considered for wider use, if proven successful.
The researchers will be giving the drug BI 907828 to patients and closely watching for any side effects, also known as 'adverse events.' They will be particularly interested in how often these side effects occur, how severe they are, and if any lead to patients needing to stop the treatment, reduce the dose, or delay a dose. Safety is a top priority in these types of studies.
Beyond safety, the study will also measure how well the drug works against the cancer. This includes looking at whether the tumors shrink or disappear, how long patients live without their cancer getting worse, and how long they live overall. They'll also check if the disease is controlled, meaning it doesn't grow or spread. This information is crucial for understanding the potential benefits of BI 907828 for people with dedifferentiated liposarcoma.
Key takeaways
- Brightline-4 is a study for a new drug called BI 907828.
- It's for adults with advanced dedifferentiated liposarcoma.
- The study aims to check how safe and effective the drug is.
- Participation involves regular clinic visits and health checks.
- You can stop participating at any time.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
This study is specifically for people who have advanced dedifferentiated liposarcoma, which means your cancer has spread beyond the original site. You might be eligible whether you haven't received any treatment for your advanced cancer yet, or if you have tried other treatments in the past.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with advanced dedifferentiated liposarcoma?
- Are you able to attend regular appointments for treatment and check-ups?
- Are you willing to potentially try a new, experimental medication?
What does participation involve?
If you decide to join this study, you will receive the study drug, BI 907828. You would have regular visits to the hospital or clinic so the study team can monitor your health, check for any side effects, and see how the treatment is affecting your cancer. These visits would involve various tests, such as blood tests, scans (like CT scans), and physical exams to track your progress.
The study team will carefully explain the schedule of these visits and what each visit will involve. They will also tell you how long you are expected to take the treatment and what kind of follow-up care you will receive after the treatment period ends. Overall, your participation would involve consistent check-ups and taking the study medication for a period, which will be determined by your response to the treatment and the study's design.
Potential risks and benefits
Locations (2)
- —UnverifiedBelgium
- —UnverifiedItaly
Common questions
What is dedifferentiated liposarcoma?
It's a type of cancer that develops in the soft, fatty tissues of your body.
What does a 'Phase III' study mean?
This means it's a later stage study, often comparing a new treatment to existing ones, or confirming its benefits and safety in a larger group of people.
Will I definitely get the new drug?
Yes, in this particular study, all participants will receive the new drug, BI 907828, as it's a 'single-arm' study.
What are 'treatment-emergent adverse events'?
These are any unexpected medical problems or side effects that happen during or after you start the study treatment.
How will they know if the drug is working?
Doctors will use scans and other tests to see if your tumors are shrinking, staying the same, or getting bigger, and monitor how you feel overall.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.